Gulf War and Health

VOLUME 4

HEALTH EFFECTS OF SERVING IN THE GULF WAR

Committee on Gulf War and Health: A Review the Medical Literature Relative to the Gulf War Veterans’ Health

Board on Population Health and Public Health Practice

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS
Washington, D.C
www.nap.edu
“Knowing is not enough; we must apply.  
Willing is not enough; we must do.”
—Goethe
The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.

The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Wm. A. Wulf is president of the National Academy of Engineering.

The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Wm. A. Wulf are chair and vice chair, respectively, of the National Research Council.
COMMITTEE ON GULF WAR AND HEALTH: A REVIEW OF THE MEDICAL LITERATURE RELATIVE TO GULF WAR VETERANS’ HEALTH

LYNN R. GOLDMAN, MD, MPH, (chair) Professor, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
MARCIA ANGELL, MD, Senior Lecturer on Social Medicine, Department of Social Medicine, Harvard Medical School, Boston, MA
W. KENT ANGER, PhD, Associate Director for Occupational Research, Center for Research on Occupational and Environmental Toxicology, Oregon Health and Science University, Portland, OR
MICHAEL BRAUER, ScD, Professor, School of Occupational and Environmental Hygiene, University of British Columbia, Vancouver, British Columbia
DEDRA S. BUCHWALD, MD, Director, Harborview Medical Center, University of Washington, Seattle, WA
FRANCESCA DOMINICI, PhD, Associate Professor, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
ARTHUR L. FRANK, MD, PhD, Professor, Chair, Department of Environmental and Occupational Health, Drexel University School of Public Health, Philadelphia, PA
FRANCINE LADEN, ScD, Assistant Professor of Medicine, Channing Laboratory, Harvard Medical School, Boston, MA
DAVID MATCHAR, MD, Director, Center for Clinical Health Policy Research, Duke University Medical Center, Durham, NC
SAMUEL J. POTOLICCHIO, MD, Professor, Department of Neurology, George Washington University Medical Center, Washington, DC
THOMAS G. ROBINS, MD, MPH, Professor, Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI
GEORGE W. RUTHERFORD, MD, Professor, Vice-Chair, Department of Epidemiology and Biostatistics, Division of Preventive Medicine and Public Health, School of Medicine, University of California, San Francisco, CA
CAROL A. TAMMINGA, M.D., Professor, Department of Psychiatry, University of Texas, Southwestern Medical Center, Dallas, TX
STAFF

CAROLYN FULCO, Senior Program Officer
ABIGAIL MITCHELL, Senior Program Officer
DEEPALI PATEL, Senior Program Associate
MICHAEL SCHNEIDER, Senior Program Associate
JUDITH URBANCZYK, Senior Program Associate
HOPE HARE, Administrative Assistant
PETER JAMES, Research Associate
DAMIKA WEBB, Research Assistant
RENEE WLODARZYK, Intern
NORMAN GROSSBLATT, Senior Editor
ROSE MARIE MARTINEZ, Director, Board on Population Health and Public Health Practice

CONSULTANTS

MIRIAM DAVIS, Independent Medical Writer, Silver Spring, Maryland
ANNE STANGL, Tulane School of Public Health and Tropical Medicine, New Orleans, LA
This report has been reviewed in draft form by persons chosen for their diverse perspectives and technical expertise in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following for their review of this report:

ARThUR K Asbury, MD, Department of Neurology, University of Pennsylvania, Philadelphia, PA
SHARON COOPER, PhD, Professor and Chair, Department of Epidemiology and Biostatistics, Texas A & M University School of Rural Public Health, College Station, TX
PEtER J. DyCK, MD, Director, Peripheral Nerve Research Laboratory, Mayo Clinic College of Medicine, Rochester, MN
DAVID GAYLOR, PhD, MS, President, Gaylor & Associates, LLC, Eureka Springs, AR
JACK M GORMAN, MD, President and Psychiatrist in Chief, McLean Hospital, Belmont, MA
PHILIP GREENLAND, MD, Executive Associate Dean for Clinical and Translational Research, Northwestern University Feinberg School of Medicine, Chicago, IL
HOWARD KIPEN, MD, MPH, Director, Clinical Research and Occupational Medicine Division, Environmental & Occupational Health Sciences Institute, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ
JOSEPH LADOu, MD, Editor, International Journal of Occupational and Environmental Health, Professor, Division of Occupational and Environmental Medicine, University of California, San Francisco, CA
ELLEN REMENCHIK, MD, MPH, Assistant Professor, Occupational and Environmental Medicine, The University of Texas Health Center, Tyler, TX
KATHERINE S. SQUIBB, PhD, Associate Professor & Head, Division of Environmental Epidemiology & Toxicology, University of Maryland School of Medicine, Baltimore, MD

Although the reviewers listed above have provided many constructive comments and suggestions, they were not asked to endorse the conclusions or recommendations nor did they see the final draft of the report before its release. The review of this report was overseen by David J. Tollerud, Professor and Chair, Department of Environmental and Occupational Health Sciences, University of Louisville and by Harold Sox, editor, Annals of Internal Medicine, American College of Physicians of Internal Medicine. Appointed by the National Research Council, Dr. Sox was responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this report rests entirely with the authoring committee and the institution.
The 1990-1991 Persian Gulf War was brief and entailed few US casualties in comparison with other wars, and yet it had a profound impact on the lives of many of the troops. Among the 700,000 US military personnel deployed in the battle theater, many veterans have reported chronic symptoms and illnesses that they have attributed to their service in the gulf. Numerous studies have been conducted to characterize the long-term adverse health consequences of deployment to the Persian Gulf.

Potential exposures to numerous hazardous substances have been identified in association with the Gulf War. Most alarming are the smoke from oil-well fires that were set by Iraqis as they retreated at the end of the war and the potential exposures arising from the US military bombing of a poison-gas munitions dump at a location called Khamisiyah. Military personnel have also been reported to have had other exposures, such as to fuels, vaccines, pharmaceuticals, and pathogens. Most recently, the Department of Defense published a report documenting a large amount of pesticide use in the war theater. For most of those exposures, it is difficult or impossible to reconstruct doses because of lack of exposure measurements on either the individual or group level. The situation is compounded by the stress experienced by many veterans during deployment and in some cases after deployment. Stress is known to have serious acute and chronic health effects, but at the time of the Gulf War relatively little attention was given to reduction of stress and its consequences.

The Department of Veterans Affairs (VA) and the US Congress have secured the assistance of the Institute of Medicine (IOM) in evaluating the scientific literature regarding possible health outcomes associated with exposures that might have occurred in the Gulf War, IOM has published several volumes that review the clinical diseases that might be associated with exposures, such as exposure to sarin gas, depleted uranium, pesticides, solvents, rocket propellants, fuels, and combustion products. Such reviews continue and will provide information about illnesses related to exposure to pathogens, stress, and chemical agents. The congressional request regarding the possible association between illness and exposures in the gulf is similar to the approach Congress took after the Vietnam War to address the potential adverse health effects of exposure to Agent Orange.

The current report, however, takes a different approach, which is to identify the adverse health effects, if any, that are occurring among Gulf War veterans and thus might warrant further attention, either on the individual level or for the Gulf War veterans as a whole. Many of the relevant studies are limited by the lack of objective exposure information. Although there is a blood test that can provide an indication of exposure to Agent Orange and dioxin that occurred many years ago, there is not biological measure that can be employed today to assess exposures during the Gulf War. Another limitation is that most studies have relied on self-reports of symptoms and symptom-based case definitions to determine whether rates of diseases were increased among Gulf War veterans. Nonetheless, some studies do point to psychiatric disorders and neurologic end points that might be associated with Gulf War service and for which it might be possible to develop new approaches to prevention and clinical treatment that could benefit not only Gulf War veterans but also veterans of later conflicts. Our committee does not recommend
that more such studies be undertaken for the Gulf War Veterans, but, there would be value in continuing to monitor the veterans for some health end points, specifically, cancer, especially brain and testicular cancers, neurologic diseases including Amyotrophic Lateral Sclerosis (ALS), and causes of death. Therefore, despite the serious limitations of the available studies as a group, they do point the way to actions that might benefit Gulf War and other combat veterans.

I am deeply appreciative of the expert work of our committee members: Marcia Angell, W. Kent Anger, Michael Brauer, Dedra S. Buchwald, Francesca Dominici, Arthur L. Frank, Francine Laden, David Matchar, Samuel J. Potolicchio, Thomas G. Robins, George W. Rutherford, and Carol Tamminga. Although our committee developed conclusions independently of input from IOM and its staff, we deeply appreciate their hard work and attention to detail and the extensive research that they conducted to ensure that we had all the information that we needed from the outset. It has been a privilege and a pleasure to work with the IOM staff directed by Carolyn Fulco and with our consultant, Miriam Davis. Without them, this report would not have been possible. Most of all, our committee appreciates the veterans who served in the Gulf War and who have volunteered again and again to participate in the health studies that we reviewed. It is for them that we do this work. We hope this report will inform those who have given so much to our nation about what researchers have been able to learn about their health.

LYNN R. GOLDMAN, MD, MPH
PROFESSOR
JOHNS HOPKINS UNIVERSITY
# CONTENTS

1 INTRODUCTION ..............................................................................................................11  
   Background .........................................................................................................................11  
   The Gulf War Setting ..........................................................................................................12  
   Deployment .......................................................................................................................12  
   Living Conditions .............................................................................................................13  
   Environmental and Chemical Exposures ..........................................................................13  
   Threat of Chemical and Biologic Warfare ........................................................................14  
   Charge to the Committee ....................................................................................................15  
   Committee’s Approach to its Charge ..................................................................................15  
   Inclusion Criteria .................................................................................................................15  
   Complexities in Resolving Gulf War and Health Issues .....................................................16  
   Multiple Exposures and Chemical Interactions ................................................................16  
   Limitations of Exposure Information ...............................................................................16  
   Individual Variability ........................................................................................................17  
   Unexplained Symptoms ....................................................................................................17  
   Organization of the Report ..................................................................................................18  
   References ...........................................................................................................................18  

2 EXPOSURES IN THE PERSIAN GULF ...........................................................................21  
   Exposure Assessment in Epidemiologic Studies ...............................................................21  
   Studies Assessing Exposures with Questionnaires .............................................................21  
   Exposure to Oil-Well Fire Smoke ....................................................................................22  
   Exposure to Vaccination ...................................................................................................22  
   Exposure to Pyridostigmine Bromide ...............................................................................23  
   Exposure to Depleted Uranium ........................................................................................24  
   General Cohort Studies (Prevalence Studies) .....................................................................25  
   Studies Using Simulation to Assess the Potential Magnitude of Exposures .......................26  
   Tent Heaters ......................................................................................................................26  
   Khamisiyah Demolition and Potential Exposure to Sarin and Cyclosarin .......................26  
   Epidemiologic Studies Using Fate and Transport Models  
      to Assess Exposure to Sarin and Cyclosarin ................................................................35  
   Studies Using Environmental Fate and Transport Models for Specific Exposures .............37  
   Studies using Biologic Monitoring for Specific Exposures ..............................................39  
   Depleted Uranium .............................................................................................................39  
   Oil-Well Fire Smoke .........................................................................................................40  
   Summary and Conclusions ...............................................................................................41
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary and Conclusion (ICD-10 F00-F99)</td>
<td>118</td>
</tr>
<tr>
<td>Mental and Behavioral Disorders (ICD-10 F00-F99)</td>
<td>122</td>
</tr>
<tr>
<td>Psychiatric Outcomes</td>
<td>122</td>
</tr>
<tr>
<td>Primary Studies</td>
<td>123</td>
</tr>
<tr>
<td>Secondary Studies</td>
<td>127</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>127</td>
</tr>
<tr>
<td>Neurobehavioral and neurocognitive Outcomes (ICD-10 F00-F99)</td>
<td>131</td>
</tr>
<tr>
<td>Neurobehavioral Tests and Confounding Factors</td>
<td>131</td>
</tr>
<tr>
<td>Studies That Respond to Question 1 (Outcomes in Gulf War-Deployed Veterans vs Veterans Deployed Elsewhere or Not Deployed)</td>
<td>132</td>
</tr>
<tr>
<td>Studies That Respond to Question 2 (Symptomatic vs Nonsymptomatic Veterans)</td>
<td>135</td>
</tr>
<tr>
<td>Related Findings: Malingering and Association of Symptoms with Objective Test Results</td>
<td>140</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>140</td>
</tr>
<tr>
<td>Diseases of the Nervous System (ICD-10 G00-G99)</td>
<td>153</td>
</tr>
<tr>
<td>Primary Studies</td>
<td>153</td>
</tr>
<tr>
<td>Secondary Studies</td>
<td>154</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>155</td>
</tr>
<tr>
<td>Peripheral Neuropathy and Other Neurologic Outcomes</td>
<td>157</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>159</td>
</tr>
<tr>
<td>Chronic Fatigue Syndrome</td>
<td>161</td>
</tr>
<tr>
<td>Primary Studies</td>
<td>162</td>
</tr>
<tr>
<td>Secondary Studies</td>
<td>162</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>163</td>
</tr>
<tr>
<td>Diseases of the circulatory System (ICD-10 I00-I99)</td>
<td>166</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>166</td>
</tr>
<tr>
<td>Primary Studies</td>
<td>166</td>
</tr>
<tr>
<td>Secondary Studies</td>
<td>167</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>168</td>
</tr>
<tr>
<td>Diseases of the Respiratory System (ICD-10 J00-J99)</td>
<td>170</td>
</tr>
<tr>
<td>Associations of Respiratory Outcomes with Deployment in the Gulf War Theater</td>
<td>170</td>
</tr>
<tr>
<td>Primary Studies</td>
<td>170</td>
</tr>
<tr>
<td>Secondary Studies</td>
<td>171</td>
</tr>
<tr>
<td>Associations of Respiratory Outcomes with Specific Exposures Experienced by Gulf War Veterans During Their Deployment</td>
<td>172</td>
</tr>
<tr>
<td>Exposure to Oil-Well Fire Smoke</td>
<td>172</td>
</tr>
<tr>
<td>Exposure to Nerve Agents</td>
<td>174</td>
</tr>
<tr>
<td>Other Exposures</td>
<td>174</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>174</td>
</tr>
<tr>
<td>Associations of Respiratory Outcomes with Deployment in the Gulf War Theater</td>
<td>174</td>
</tr>
<tr>
<td>Associations of Respiratory Symptoms, Signs, and Illnesses with Specific Exposures Experienced by Gulf War Veterans During Their Deployment</td>
<td>175</td>
</tr>
<tr>
<td>Diseases of the Digestive System (ICD-10 K00-K93)</td>
<td>180</td>
</tr>
<tr>
<td>Primary Studies</td>
<td>180</td>
</tr>
<tr>
<td>Secondary Studies</td>
<td>181</td>
</tr>
<tr>
<td>Summary and Conclusion</td>
<td>181</td>
</tr>
</tbody>
</table>
Diseases of the Skin and Subcutaneous Tissue (ICD-10 L00-L99) ................................................................. 183
Primary Studies ................................................................................................................................. 183
Secondary Studies ............................................................................................................................. 183
Summary and Conclusion .................................................................................................................. 183
Diseases of the Musculoskeletal system and Connective Tissue (ICD-10 M00-M99) ................................................................. 185
Arthritis and Arthralgia ...................................................................................................................... 185
Primary Studies ................................................................................................................................. 185
Secondary Studies ............................................................................................................................. 185
Summary and Conclusion .................................................................................................................. 186
Fibromyalgia ........................................................................................................................................ 188
Primary Studies ................................................................................................................................. 188
Secondary Studies ............................................................................................................................. 189
Summary and Conclusion .................................................................................................................. 190
Birth Defects and Adverse Pregnancy Outcomes (ICD-10 O00-Q99) ..................................................... 192
Birth Defects ...................................................................................................................................... 192
Primary Studies ................................................................................................................................. 192
Secondary Studies ............................................................................................................................. 193
Goldenhar Syndrome ....................................................................................................................... 194
Summary and Conclusion .................................................................................................................. 194
Adverse Pregnancy Outcomes ........................................................................................................... 195
Primary Study .................................................................................................................................... 195
Secondary Studies ............................................................................................................................. 195
Summary and Conclusion .................................................................................................................. 195
Male Fertility Problems and Infertility ............................................................................................... 196
Primary Studies ................................................................................................................................. 196
Summary and Conclusion .................................................................................................................. 196
Symptoms, Signs, and Abnormal Clinical and Laboratory Findings (ICD-10 R00-R99) ....................... 202
Unexplained Illness ............................................................................................................................. 202
Hospitalizations for Unexplained Illness ......................................................................................... 202
Factor-Analysis Derived Syndromes ............................................................................................... 203
Primary Studies ................................................................................................................................. 203
Cluster Analysis .................................................................................................................................. 212
Summary and Conclusion .................................................................................................................. 213
Injury and External Causes of Morbidity and Mortality (ICD-10 S00-Y98) ........................................... 219
Primary Studies ................................................................................................................................. 219
Secondary Studies ............................................................................................................................. 220
Summary and Conclusion .................................................................................................................. 220
All-Cause Hospitalization Studies ..................................................................................................... 223
Primary Studies ................................................................................................................................. 223
Summary and Conclusion .................................................................................................................. 224
Multiple Chemical Sensitivity .......................................................................................................... 227
Primary Studies ................................................................................................................................. 227
Secondary Studies ............................................................................................................................. 228
Summary and Conclusion .................................................................................................................. 229
6 CONCLUSIONS AND RECOMMENDATIONS ...........................................................247

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>quality of the studies</td>
<td>247</td>
</tr>
<tr>
<td>overview of health outcomes</td>
<td>247</td>
</tr>
<tr>
<td>Outcomes Based Primarily on Symptoms and Self-reports</td>
<td>248</td>
</tr>
<tr>
<td>Outcomes with Objective Measures or Diagnostic Medical Tests</td>
<td>251</td>
</tr>
<tr>
<td>Recommendations</td>
<td>254</td>
</tr>
<tr>
<td>Predeployment and Postdeployment Screening</td>
<td>254</td>
</tr>
<tr>
<td>Exposure Assessment</td>
<td>254</td>
</tr>
<tr>
<td>Surveillance for Adverse Outcomes</td>
<td>254</td>
</tr>
<tr>
<td>References</td>
<td>255</td>
</tr>
</tbody>
</table>
Although the 1990-1991 Persian Gulf War was considered a brief and successful military operation with few injuries and deaths among coalition forces, many returning veterans soon began reporting numerous health problems that they believed to be associated with their service in the Persian Gulf.

In 1998, in response to the growing concerns of the ill Gulf War veterans, Congress passed two laws: PL 105-277, the Persian Gulf War Veterans Act, and PL 105-368, the Veterans Programs Enhancement Act. Those laws directed the secretary of veterans affairs to enter into a contract with the National Academy of Sciences (NAS) to review and evaluate the scientific and medical literature regarding associations between illness and exposure to toxic agents, environmental or wartime hazards, and preventive medicines or vaccines associated with Gulf War service and to consider the NAS conclusions when making decisions about compensation. Those studies were assigned to the Institute of Medicine (IOM).

This study, conducted at the request of the Department of Veterans Affairs (VA), differs from the previous work of IOM in that it summarizes in one place the current status of health effects in veterans deployed to the Persian Gulf irrespective of exposure information. One can confidently assess health responses associated only with deployment in the Gulf War Theater. Estimating the veterans’ health risks associated with particular environmental exposures is challenged by the lack of exposure monitoring and of biomarkers to quantify individual exposures of veterans during the deployment retrospectively.

CHARGE TO THE COMMITTEE

The charge to this IOM committee was to review, evaluate, and summarize peer-reviewed scientific and medical literature addressing the health status of Gulf War veterans. The study was to help to inform the VA of illnesses among Gulf War veterans that might not be immediately evident.

COMMITTEE’S APPROACH TO ITS CHARGE

The committee began its evaluation by presuming neither the existence nor the absence of illnesses associated with deployment. It sought to characterize and weigh the strengths and limitations of the available evidence. The committee did not concern itself with policy issues, such as decisions regarding disability, potential costs of compensation, or any broad policy implications of its findings.
Extensive searches of the scientific and medical literature were conducted, and over 4,000 potentially relevant references were retrieved. After assessment of the titles and abstracts references found in of the initial searches, the committee focused on 850 potentially relevant epidemiologic studies for its review and evaluation.

The committee limited its review of the literature primarily to epidemiologic studies of Gulf War veterans to determine the prevalence of diseases and symptoms in that population. Those studies typically examine veterans’ health outcomes in comparison with outcomes in their nondeployed counterparts.

The committee decided to use only peer-reviewed published literature on which to base its conclusions. The process of peer review by fellow professionals increases the likelihood of a high-quality study but does not guarantee its validity or the generalizability of its findings to the entire group of subjects under review. Accordingly, committee members read each study critically and considered its relevance and quality. The committee did not collect original data, nor did it perform any secondary data analysis (exception to calculate response rates for consistency among studies).

After securing the full text of the peer-reviewed epidemiologic studies it would review, the committee determined which studies would be considered primary or secondary studies. Primary studies provide the basis of the committee’s findings. To be included in the committee’s review as a primary study, a study had to meet specified criteria. The criteria include studies that provide information about specific health outcomes, demonstrate rigorous methods, describe its methods in sufficient detail, include a control or reference group, have the statistical power to detect effects, and include reasonable adjustments for confounders. Other studies were considered secondary for the purpose of this review and provided background information or “context” for the report. Another step that the committee took in organizing its literature was to determine how all the studies were related to one another. Numerous Gulf War cohorts have been assembled, from several different countries; from those original cohorts many derivative studies have been conducted. The committee organized the literature into the major cohorts and derivative studies because they didn’t want to interpret the findings of the same cohorts as though they were results from unique groups (Chapter 4).

**LIMITATIONS OF THE GULF WAR STUDIES**

Overall, the studies of Gulf War veterans’ health are of varied quality. Although, they have provided valuable information, many of them have limitations that hinder accurate assessment of the veterans’ health status. Common study limitations include use of a population that was not representative of the entire Gulf War population, reliance on self-reports rather than objective measures of symptoms, low participation rates, and a period of investigation that was too brief to detect health outcomes with long latency such as, cancer. In addition, many of the US studies are cross-sectional, and this limits the opportunity to learn about symptom duration, long-term health effects, latency of onset, and prognosis.
OVERVIEW OF HEALTH OUTCOMES

While examining health outcomes in Gulf War-deployed veterans, numerous researchers have attempted to determine whether a set of symptoms reported by veterans could be defined as a unique syndrome or illness. Investigators have attempted, by using factor or cluster analysis, to define a unique health outcome, but none has been identified. Every study reviewed by this committee found that veterans of the Gulf War report higher rates of nearly all symptoms examined than their nondeployed counterparts. That finding was applied not only to Gulf War veterans from the United States but also to the Gulf War veterans deployed from the UK, Canada, Australia, and Denmark. Some studies examined performance on neurocognitive tests in association with symptoms that were considered possibly indicative of neurological or cognitive impairment (such as headache, confusion, and memory problems). Those few studies seemed to indicate that Gulf War veterans with such symptoms demonstrated neurobehavioral deficits, but, most of the studies did not include control groups (or, in some cases, valid control groups).

In many studies, investigators found a higher prevalence not only of individual symptoms but also of chronic multisymptom illnesses among Gulf War-deployed veterans than among the nondeployed. Multisymptom-based medical conditions reported to occur more frequently among deployed Gulf War veterans include fibromyalgia, chronic fatigue syndrome (CFS), and multiple chemical sensitivity (MCS). However, the case definitions for those conditions are based on symptom reports, and there are no objective diagnostic criteria that can be used to validate the findings, so, it is not clear whether the literature supports a true excess of the conditions or whether the associations are spurious and result from the increased reporting of symptoms across the board. The literature also demonstrates that deployment places veterans at increased risk for symptoms that meet diagnostic criteria for a number of psychiatric illnesses, particularly posttraumatic stress disorder (PTSD), anxiety, depression, and substance abuse. In addition, comorbidities have been reported, for example, symptoms of both PTSD and depression. The committee felt confident that several studies validated the increased risk of psychiatric disorders.

Some studies indicate that Gulf War veterans are at increased risk for amyotrophic lateral sclerosis (ALS). With regard to birth defects, there is weaker evidence that Gulf War veterans’ offspring might be at risk for some birth defects; the findings are inconsistent. There were increased rates of transportation-related injuries and mortality among deployed Gulf War veterans, however, that increase appears to have been restricted to the first several years after the war. Finally, long-term exacerbation of asthma appeared to be associated with oil-well fire smoke, but there were no objective measures of pulmonary function in the studies.

The health outcomes presented above are discussed in some detail in the following pages. They are grouped according to whether the findings were based on objective measures and diagnostic medical tests.

Outcomes Based Primarily on Symptoms or Self-reports

The largest and most nationally representative survey of US veterans found that nearly 29% of deployed veterans met a case definition of "multisymptom illness", compared with 16% of nondeployed veterans. Those figures indicate that unexplained illnesses are the most prevalent health outcome of service in the Gulf War. Several researchers have tried to determine whether the symptoms that have been reported by Gulf War veterans cluster in such a way as to make up
a unique syndrome, such as “Gulf War illness”. The results of that research indicate that although deployed veterans report more symptoms and more severe symptoms than their nondeployed counterparts, there is not a unique symptom complex (or syndrome) in deployed Gulf War veterans.

Among the many symptoms reported by Gulf War veterans are deficits in neurocognitive ability. Obviously such reports are of concern because of the potential for those deficits to have adverse effects on the lives of the veterans. Primary studies of deployed Gulf War veterans and non-Gulf War-deployed veterans, however, have not demonstrated differences in cognitive and motor measures as determined with neurobehavioral testing. But studies of returning Gulf War veterans with at least one commonly reported symptom (fatigue, memory loss, confusion, inability to concentrate, mood swings, somnolence, gastrointestinal distress, muscle and joint pain or skin or mucous-membrane complaints) demonstrated poorer performance on cognitive tests than by returning Gulf War veterans who did not report such symptoms. Most of those studies did not include control groups (or in some cases valid control groups) so it is not possible to determine whether the combination of symptoms and neurocognitive-test decrements is uniquely associated with Gulf War service.

Several studies focused on multisymptom-based medical conditions: fibromyalgia, CFS, and MCS. Those conditions have several features in common: they do not fit a precise diagnostic category; case definitions are symptom-based (supplemented, in the case of fibromyalgia, by report of pain on digital palpation of tender points in a physical examination); there are no objective criteria independent of patient reports, such as laboratory test results, for validating the case definitions; and the symptoms among those syndromes are to some extent overlapping. Gulf War-deployed veterans report higher rates of symptoms that are consistent with the case definitions of MCS, CFS, and fibromyalgia.

Several large or population-based studies of Gulf War veterans found, by questionnaire, that the prevalence of MCS-like symptoms ranged from 2% to 6%. However, no two of the primary studies used the same definition of MCS, so it is difficult to compare them, and none performed medical evaluations to exclude other explanations, as would be required by the case definition of MCS.

The prevalence of CFS among Gulf War veterans is highly variable from study to study; most studies used the Centers for Disease Control and Prevention case definition. One primary study demonstrated a higher prevalence of CFS in deployed than in nondeployed veterans (1.6% vs 0.1%). Secondary studies also showed a higher prevalence of CFS and CFS-like illnesses among veterans deployed to the Persian Gulf than in to their counterparts who were not deployed or who were deployed elsewhere.

The diagnosis of fibromyalgia is based on symptoms and a very limited physical examination that consists of determining whether pain is elicited by pressing on several points on the body; there are no laboratory tests with which to confirm the diagnosis. Only one of the available cross-sectional studies included both Gulf War-deployed and -nondeployed veterans and used the full American College of Rheumatology case definition of fibromyalgia, including the physical-examination criteria. It found a statistically significant difference in prevalence of fibromyalgia between deployed and nondeployed veterans (2.0% vs 1.2%). Other studies using a case definition based on symptoms alone reported inconsistent results.
Other symptoms that are self-reported more often by deployed veterans are gastrointestinal symptoms, particularly dyspepsia; dermatologic conditions, particularly atopic dermatitis and warts; and joint pains.

There were many reports of gastrointestinal symptoms in Gulf War-deployed veterans. Those symptoms seem to be linked to reports of exposures to contaminated water and burning of animal waste in the war theater. The committee notes that several studies reported a higher rate of self-reported dyspepsia in deployed Gulf War veterans than in nondeployed veterans. In the context of nearly all symptoms being reported more frequently for Gulf War veterans, it is difficult to interpret those findings.

For dermatologic conditions, a few studies have included an examination of the skin and thus would be more reliable than self-reports. Those studies have reported that a few unrelated skin conditions occurred more frequently among Gulf War-deployed veterans; however, the findings are not consistent. From one study that did conduct a skin examination, there is some evidence of a higher prevalence of two distinct dermatologic conditions, atopic dermatitis and verruca vulgaris (warts), in Gulf War-deployed veterans.

Arthralgias (joint pains) were more frequently reported among Gulf War veterans. Likewise, self-reports of arthritis were more common among those deployed to the gulf. Again, in the context of global reporting increases, such data are difficult to interpret. Moreover, studies that included a physical examination did not find evidence of an increase in arthritis.

Finally, Gulf War veterans consistently have been found to suffer from a variety of psychiatric conditions. Two well-designed studies using validated interview-based assessments reported that several psychiatric disorders, most notably PTSD and depression, are 2-3 times more likely in Gulf War-deployed than in nondeployed veterans. Moreover, comorbidities were reported among a number of veterans, with co-occurrence of PTSD, depression, anxiety, or substance abuse. Most of the additional studies administered well-validated symptom questionnaires, and the findings were remarkably similar: an overall increase by a factor of 2-3 in the prevalence of psychiatric disorders.

**Outcomes with Objective Measures or Diagnostic Medical Tests**

A number of studies examined rates of injuries in Gulf War veterans. Those studies provide evidence of a modest increase in transportation-related injuries and deaths among deployed than among non-deployed Gulf War veterans in the decade immediately after deployment. However, studies with longer followup indicate that the increased injury rate was restricted to the first several years after the war.

With regard to all causes of hospitalization, studies provide some reassurance that excess hospitalizations did not occur among veterans of the Gulf War who remained on active duty through 1994, inasmuch as it has been noted that Gulf War veterans who left the military reported worse health outcomes than those who remained. Those studies, however, are limited by their inability to capture hospitalizations from illnesses that might have longer latency, such as some cancers. In addition, hospitalization data on people separated from the military and admitted to nonmilitary (Department of Veterans Affairs [VA] and civilian) hospitals or those who used outpatient facilities might be incomplete.
Veterans are understandably concerned about increases in cancer, and the studies reviewed did not demonstrate consistent evidence of increased overall cancer in the Gulf War veterans compared with nondeployed veterans. However, many veterans are young for cancer diagnoses, and, for most cancers, the time since the Gulf War is probably too short to expect the onset of cancer. Incidence of and mortality from cancer in general and brain and testicular cancer in particular have been assessed in cohort studies. An association of brain-cancer mortality with possible nerve-agent exposure was observed in one study, but however, there were many uncertainties in the exposure model used. Results for testicular cancer were mixed: one study concluded that there was no evidence of an excess risk, and another, small registry-based study suggested that there might be an increased risk.

Another concern for veterans has been whether ALS is increased in Gulf War veterans. Two primary studies and one secondary study found that deployed veterans appear to be at increased risk of ALS. One primary study that had the possibility of underascertainment of cases in the nondeployed population was confirmed by a secondary analysis that documented a nearly 2-fold increase in risk. A secondary study that used general population estimates as the comparison group found a slightly higher relative risk.

Peripheral neuropathy has been studied in Gulf War veterans. One large, well-designed study conducted by VA which used a thorough and objective evaluation and a stringent case definition, did not find evidence of excess peripheral neuropathy. Several other secondary studies supported no excess risk. Thus, there does not appear to be an increase in the prevalence of peripheral neuropathy in deployed vs nondeployed veterans, as defined by history, physical examination, and electrophysiologic studies.

With regard to cardiovascular disease, primary studies found no significant differences between deployed and nondeployed veterans in rates of hypertension. One study did report a small but significant increase in hospitalizations due to cardiovascular disease among a subset of deployed veterans who were possibly exposed to the Khamisiyah plume compared with Gulf War-deployed veterans who were not in the suspected exposure area. The increased hospitalizations were due entirely to an increase in cardiac dysrhythmias. In secondary studies, deployed veterans were generally more likely to report hypertension and palpitations, but those reports were not confirmed with medical evaluations. Thus, it does not appear that there is a difference in the prevalence of cardiovascular disease or diabetes between deployed Gulf War veterans and nondeployed.

Many veterans are understandably concerned about the possibility of birth defects in their offspring. Two primary studies yielded some evidence of increased risk of birth defects among offspring of Gulf War veterans. However, the specific defects with increased prevalence (cardiac, kidney, urinary tract, and musculoskeletal abnormalities) in the two studies were not consistent. Overall, the studies are difficult to interpret because of the relative rarity of specific birth defects, use of small sample, timing of exposure (before or after conception), and whether the mother or the father was exposed. There was no consistent pattern of one of more birth defects with a higher prevalence in the offspring of male or female Gulf War veterans. Only one set of defects (that is, urinary tract abnormalities) has been found to be increased in more than one well-designed study. With regard to other adverse reproductive outcomes, the results of one primary study, which had hospital discharge data available, were suggestive of an increased risk of spontaneous abortions and ectopic pregnancies in Gulf War veterans.
Numerous studies in several countries examined respiratory outcomes related to deployment to the Gulf War Theater. The overwhelming majority of studies conducted among Gulf War veterans, whether from the United States, the UK, Canada, Australia, or Denmark, have found that several years after deployment, those deployed report higher rates of respiratory symptoms and respiratory illnesses than nondeployed troops. However, in all five studies, representing four distinct cohorts from three countries (the United States, Australia, and Denmark) that examined associations of Gulf War deployment with pulmonary-function measures or respiratory disease diagnoses based in part on such measures, such associations were not found. The uniformity of the findings is striking, especially given that the same five studies found that Gulf War deployment status was significantly associated with self-reports of respiratory symptoms among three of the four cohorts.

Whereas the studies discussed above examined respiratory outcomes associated simply with deployment vs nondeployment, other studies examined respiratory outcomes associated with specific environmental exposures experienced by Gulf War veterans, including exposure to oil-well fires and nerve agents. The methodologically strongest such study used objective exposure measures and methods and found significant associations between exposure to oil-well fire smoke and a doctor-assigned diagnosis of asthma in veterans. However, the strongest study was limited by the self-selection of participants. A second study, which had the advantage of being population-based, had the key limitation that case definitions were purely symptom-based, and it did not find associations between the same objective measures of exposure to oil-well fire smoke and asthma symptoms. A third study found no significant associations between the same objective measures of exposure to smoke from oil-well fires and later hospitalization for asthma, acute bronchitis, chronic bronchitis, or emphysema; however, the participants were all active-duty veterans, and young adults are seldom hospitalized for those diagnoses, so most cases would not be expected to be captured.

With regard to modeled exposure to nerve agents at Khamisiyah, one study found a small increase in postwar hospitalization for respiratory system disease. However, limitations of that study include probable substantial exposure misclassification based on Department of Defense (DOD) exposure estimates that were later revised, lack of control for tobacco-smoking, lack of a clear dose-response pattern, and low biologic plausibility for this target organ system in a setting in which no effect on nervous system diseases was seen. A second study using revised DOD exposure estimates found no associations between pulmonary-function measures and exposure to nerve agents at Khamisiyah.

RECOMMENDATIONS

The adequacy of the government’s response has been both praised and criticized, VA and DOD have expended enormous effort and resources in attempts to address the numerous health issues related to the Gulf War veterans. The information obtained from those efforts, however, has not been sufficient to determine conclusively the origins, extent, and potential long-term implications of health problems potentially associated with veterans’ participation in the Gulf War. The difficulty in obtaining meaningful answers, as noted by numerous past Institute of Medicine committees and the present committee agrees, is due largely to inadequate predeployment and postdeployment screening and medical examinations, and lack of monitoring of possible exposures of deployed personnel.
Predeployment and Postdeployment Screening

Predeployment and postdeployment data-gathering needs to include physician verification of data obtained from questionnaires so that one could have confidence in baseline and postdeployment health data. Collection and archiving of biologic samples might enable the diagnosis of specific medical conditions and provide a basis of later comparison. Meticulous records of all medications, whether used for treatment or prophylactically, would have improved the data and their interpretation in many of the studies reviewed.

Exposure Assessment

Environmental exposures were usually not assessed directly, and that critically hampers the assessment of the effects of specific exposures on specific health outcomes. There have been detailed and laudable efforts to simulate and model exposures, but those efforts have been hampered by lack of the input data required to link the exposure scenarios to specific people or even to specific units or job categories. Moving beyond the current state requires that more detailed information be gathered during future military deployments. Specifically, working toward the development of a job-task-unit-exposure matrix in which information on people with specific jobs or tasks or attached to specific units (according to routinely available records) is linked to exposures by expert assessment or simulation studies would enable quantitative assessment of the effects of specific exposures.

Surveillance for Adverse Outcomes

The committee noted that several health outcomes seemed to be appearing with higher incidence or prevalence in the Gulf War-deployed veterans. For those outcomes, the committee recommends continued surveillance to determine whether there is actually a higher risk in Gulf War veterans. Those outcomes are cancer (particularly brain and testicular), ALS, birth defects (including Goldenhar syndrome and urinary tract abnormalities) and other adverse pregnancy outcomes (such as, spontaneous abortion and ectopic pregnancy), and postdeployment psychiatric conditions. The committee also recommends that cause-specific mortality in Gulf War veterans continue to be monitored. Although there was an increase in mortality in the first few years after the Gulf War, the deaths appear to have been related to transportation injuries.
### Outcomes Based Primarily on Symptoms or Self-reports

- No unique syndrome, unique illness, or unique symptom complex in deployed Gulf War veterans. Veterans of the Gulf War report higher rates of nearly all symptoms or sets of symptoms than their nondeployed counterparts; 29% of veterans meet a case definition of "multisymptom illness," as compared with 16% of nondeployed veterans.
- Multisymptom-based medical conditions reported to occur more frequently among deployed Gulf War veterans include fibromyalgia, chronic fatigue syndrome, and multiple chemical sensitivity (MCS).
- Deployment places veterans at increased risk for symptoms that meet diagnostic criteria for a number of psychiatric illnesses, particularly post traumatic stress disorder (PTSD), anxiety, depression, and substance abuse. In addition, co-morbidities were reported among a number of veterans, with PTSD, depression, anxiety, and/or substance abuse.
- Studies of deployed Gulf War veterans vs non-Gulf War deployed have not demonstrated differences in cognitive and motor measures as determined through neurobehavioral testing.
- Studies of returning Gulf War veterans with at least one of the symptoms most commonly reported by Gulf War veterans (i.e., fatigue, memory loss, confusion, inability to concentrate, mood swings, somnolence, GI distress, muscle and joint pain, skin/mucous membrane complaints) found poorer performance on cognitive tests when compared to returning Gulf War veterans who did not report such symptoms.
- Other symptoms that appear to be self-reported more often by deployed veterans are gastrointestinal symptoms, particularly dyspepsia; dermatologic conditions, particularly atopic dermatitis and warts; and joint pains (arthralgias).

### Outcomes with Objective Measures or Diagnostic Medical Tests

- Studies of mortality provide evidence for a modest increase in transportation-related injuries and mortalities among deployed compared to non-deployed Gulf War veterans in the decade immediately following deployment. However, studies with longer followup indicate that the increased injury rate was likely to have been restricted to the first several years after the war.
- With regard to all-causes of hospitalization, excess hospitalizations did not occur among veterans of the Gulf War who remained on active duty through 1994. However, Gulf War veterans who left the military reported worse health outcomes than those who remained.
- The studies do not demonstrate consistent evidence of increased overall cancer in the Gulf War veterans compared to nondeployed veterans. Studies of testicular cancer produced inconsistent results, but the latency period for many cancers may not have been reached among Gulf War veterans.
- Studies indicate that Gulf War veterans might be at increased risk for amyotrophic lateral sclerosis (ALS).
- There does not appear to be an increase in the prevalence of peripheral neuropathy in deployed vs non-deployed veterans, as defined by history, physical examination, and electrophysiologic studies.
- It does not appear that there is a difference in the prevalence of cardiovascular disease or diabetes between deployed Gulf War veterans and nondeployed.
- Overall there is no consistent pattern of one of more birth defects with a higher prevalence for the offspring of male or female Gulf War veterans. Only one set of defects, urinary tract abnormalities, has been found to be increased in more than one well-designed study.
- Respiratory symptoms are strongly associated with Gulf War deployment when using comparison groups of non-deployed veterans in most studies addressing this question. However, studies with objective pulmonary function measures find no association between respiratory illnesses with Gulf War deployment across the four cohorts in which this has been investigated.
Specific Gulf War Exposures

Outcomes with Objective Measures or Diagnostic Medical Tests

- Among studies that examined pulmonary outcomes in associations with specific exposures in the Gulf War Theater, exacerbation of asthma associated with oil-well fire smoke has been indicated.
- With respect to nerve agents at Khamisiyah, no study using objective estimates of exposure has found associations with pulmonary function measures or physician-diagnosed respiratory disease. Another study indicated that there might be an increase in brain cancer among such veterans, however, the exposure models are highly uncertain.

RECOMMENDATIONS

- Pre- and post-deployment screening of health status
- Assessment of exposures
- Surveillance for adverse health outcomes, specifically: cancer, ALS, birth defects, adverse pregnancy outcomes, post-deployment psychiatric outcomes, and mortality.